Abstracts tagged "Myositis"

Abstract Number: 0901 • ACR Convergence 2024
Intergenic Alu Elements Are Uniquely Expressed in Dermatomyositis and Correlate with Interferon Stimulated Genes
Rayan Najjar¹, Andrew Mammen² and Tomas Mustelin¹, ¹University of Washington, Seattle, WA, ²NIH, Bethesda, MD
Background/Purpose: As genes constitute < 2% of our genomes, there is a need to explore potential roles of other genomic elements in autoimmune disease. We…
Abstract Number: 1157 • ACR Convergence 2024
Reduced Statin Use in Patients with Autoimmune Myopathies and Systemic Lupus Erythematosus Compared to Rheumatoid Arthritis and Non-Inflammatory Diseases
Shane Cameron, Liam O'Neil, Annaliese Tisseverasinghe and Christine Peschken, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatic diseases such as autoimmune myopathy (AIM), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) confer an increased risk for atherosclerotic disease. The 3-hydroxy-3-methylglutaryl-coenzyme…
Abstract Number: 1645 • ACR Convergence 2024
Antisynthetase Autoantibodies Disrupt the Function of Their Target Aminoacyl-tRNA Synthetases in Muscle Cells
Maria Casal-Dominguez¹, Iago Pinal-Fernandez², Sandra Muñoz-braceras³, Corinna preuße⁴, katherine Pak¹, Jiram Torres Ruiz⁵, Jon Musai¹, Stefania Dell'Orso⁶, Faiza Naz⁶, Shamima Islam², Gusatavo Gutierrez-Cruz², Albert Selva-O’Callaghan⁷, jose milisenda⁸, Werner Stenzel⁹ and Andrew Mammen², ¹National Institutes of health, Bethesda, MD, ²NIH, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Disease, Bethesda, MD, ⁴Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD, ⁷Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁸Hospital Clinic de Barcelona, Barcelona, Spain, ⁹Charite University, Berlin, Germany
Background/Purpose: Antisynthetase syndrome (AS) is type of myositis characterized by autoantibodies targeting aminoacyl-transfer tRNA synthetases (aaRSs), the enzymes responsible for loading the appropriate amino acid…
Abstract Number: 2071 • ACR Convergence 2024
Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset
praggya yaadav¹, Maria Rosa Pellico², Anne-Marie Russell³, Aviya Lanis⁴, Elena Nikiphorou⁵, Ioannis Parodis⁶, Sreoshy Saha⁷, Manali Sarkar⁸, Jasmine Parihar⁹, Laura Andreoli¹⁰, Vikas Agarwal¹¹ and Latika Gupta¹², and COVAD Steering Committee, COVAD Study Group, ¹Maharashtra Institute of Medical Sciences and Research, Latur, Aurangabad, India, ²University of Milan, Milan, Italy, ³Birmingham Regional Interstitial Lung Disease Service, University Hospitals Birmingham NHS Trust and Faculty of Life Sciences, University of Exeter, Exeter, UK, Birmingham, United Kingdom, ⁴Seattle Children's Hospital, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁷Mymensingh Medical College, Mymensingh, Bangladesh, ⁸MGM Medical College, Navi Mumbai, Maharashtra, India, ⁹All India Institute of Medical Science, New Delhi, Delhi, India, ¹⁰University of Brescia, Brescia, Italy, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹²Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom
Background/Purpose: Self-efficacy is crucial for chronic disease management. Given the increasing prevalence of chronic diseases, encouraging patients to actively manage their disease may be an…
Abstract Number: 2406 • ACR Convergence 2024
Neuropsychiatric Manifestations in Indian SLE Inception Cohort for Research: Prevalence, Predictors and Outcomes
Sai Yasaswini Kommaraju¹, Liza Rajasekhar², Ashish J Mathew³, Vineeta Shobha⁴, Parasar Ghosh⁵, Chengappa Kavadichanda⁶, Able Lawrence⁷, Bidyut Das⁸, Manish Rathi⁹, Ranjan Gupta¹⁰, Avinash Jain¹¹ and Amita Aggarwal¹², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ²Nizam's Institute of Medical Sciences, Madhapur, Andhra Pradesh, India, ³Christian Medical College, Vellore, Tamil Nadu, India, ⁴St. John’s Medical College, Bengaluru , India, Bangalore, India, ⁵Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁶Jawaharlal Institute of Postgraduate Medical Education and Research, pondicherry, Puducherry, India, ⁷SGPGIMS, Lucknow, Lucknow, Uttar Pradesh, India, ⁸SCB Medical College, Cuttack, Orissa, India, ⁹Postgraduate Institute of Medical Education & Research, Chandigarh, Chandigarh, India, ¹⁰All India Institute of Medical Sciences, New Delhi, Delhi, India, ¹¹Sawai Man Singh Hospital, Lucknow, Rajasthan, India, ¹²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) has a significant impact on morbidity associated with SLE. However, the prevalence of NPSLE has been reported variably based…
Abstract Number: 0329 • ACR Convergence 2024
Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores
Raisa Silva¹, Manuel Carpio Tumba², Sneha Gupta³, Latika Gupta⁴, Pedro M Machado⁵, Julie Paik⁶, Diana Louden⁷, Lesley Ann Saketkoo⁸, Sebastian E. Sattui² and Didem Saygin⁹, ¹Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center McKeesport, Pittsburgh, PA, ⁴Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom, ⁵Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Washington Libraries, Seattle, WA, ⁸New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ⁹Rush University Medical Center, Chicago, IL
Background/Purpose: The growing number of randomized clinical trials (RCTs) in idiopathic inflammatory myopathies (IIMs) points to a promising future for therapeutics in IIM. Adequate representation…
Abstract Number: 1079 • ACR Convergence 2024
Early Recognition of Myositis: Time Correlation Between Transaminases and Inflammatory Myopathy in a Community-Based Rheumatology Practice
Anjali nidhaan, Shannon Iriza, Abbie West, Michael martin and Gauri Pethe, prisma health, columbia, SC
Background/Purpose: Recognizing muscle breakdown as a potential cause of elevated transaminases is crucial in the primary care setting to facilitate early referral to rheumatology for…
Abstract Number: 1159 • ACR Convergence 2024
Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Sangmee Bae¹, Francisca Bozan², Daphne Rivero Gallegos³, Giovanni Zanframundo⁴, Sara Faghihi-Kashani⁵, iazsmin Ventura⁶, Eduardo Dourado⁷, Aravinthan Loganathan⁸, Gianluca sambataro⁹, Akira Yoshida¹⁰, Francesco Bonella¹¹, Tamera J Corte¹², Tracy J Doyle¹³, david fiorentino¹⁴, Miguel Angel Gonzalez-Gay¹⁵, marie Hudson¹⁶, Masataka Kuwana¹⁷, Antonella Notarnicola¹⁸, Andrew Mammen¹⁹, Neil McHugh²⁰, Frederick Miller²¹, Carlomaurizio Montecucco²², Chester Oddis²³, Jorge Rojas-Serrano²⁴, Jens Schmidt²⁵, Carlo Scire²⁶, Albert Selva-O’Callaghan²⁷, Victoria Werth²⁸, Lorenzo Cavagna²⁹ and Rohit Aggarwal³⁰, ¹UCLA, Los Angeles, CA, ²Hospital Clinico Universidad de Chile, Santiago, Chile, ³INER, Ciudad de México, Mexico State, Mexico, ⁴Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁶Section of Rheumatology, University of Chicago, Chicago, IL, ⁷Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁸RUH, Middle Park, Queensland, Australia, ⁹University of Catania, Catania, Italy, ¹⁰Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁶McGill University, Montreal, QC, Canada, ¹⁷Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ¹⁹NIH, Bethesda, MD, ²⁰University of Bath, Bath, United Kingdom, ²¹NIH, NIEHS, Chapel Hill, NC, ²²IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁴National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁵University Medical Center Goettingen, Göttingen, Germany, ²⁶University of Milano Bicocca, Milan, Italy, ²⁷Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, ²⁸University of Pennsylvania, Wynnewood, PA, ²⁹University of Pavia, Pavia, Italy, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Anti-synthetase syndrome (ASSD) is a subset of idiopathic inflammatory myopathy characterized by autoantibodies directed against aminoacyl tRNA synthetases. Interstitial lung disease (ILD) can be…
Abstract Number: 1729 • ACR Convergence 2024
Prophylaxis Against Pneumocystis Jerovecii Pneumonia for Patients with Systemic Autoimmune Diseases: Analysis of the Veterans Affairs Database
Karolina Lungova¹, Katherine Sherman², Mahum Mirza¹, Rohan Mehta¹ and Michael Putman³, ¹Medical College of Wisconsin, Milwaukee, WI, ²Research Division, Zablocki Veterans Affairs, Milwaukee, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Pneumocystis jirovecii Pneumonia (PJP) is an opportunistic infection that may affect immunocompromised patients. PJP prophylaxis has been recommended for some autoimmune diseases but not others.…
Abstract Number: 2072 • ACR Convergence 2024
Clinical and Laboratory Features Associated with Pulmonary Involvement in Patients with Inflamatory Myopathy
Sonja Praprotnik¹, Katja Perdan-Pikmajer², Katja Lakota³, Ziga Rotar⁴ and Alojzija Hocevar⁵, ¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ²University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ³UMC Ljubljana, Ljubljana, Slovenia, ⁴University Clinical Center, Ljubljana, Slovenia, ⁵University Medical Center Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Polymyositis (PM), dermatomyositis (DM), and anti-synthetase syndrome (AS) are conditions included among idiopathic inflammatory myopathies (IMs).. Interstitial lung disease (ILD) is one of the…
Abstract Number: 2664 • ACR Convergence 2024
BCMA-targeted Bispecific T Cell-engager Therapy of Autoimmune Disease
Laura Bucci¹, Melanie Hagen², Sebastian Boeltz², Danae-Mona Noethling², Tobias Rothe², Maria Gabriella Raimondo¹, Carlo Tur¹, Andreas Wirsching¹, Jochen Wacker¹, Aline Bozec¹, Georg Schett³ and Ricardo Grieshaber-Bouyer², ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ³Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Targeting B cells and plasma cells is a key therapeutic strategy in autoimmune disease(AID). Therapy with CD19-targeted chimeric antigen receptor (CAR) T-cells and bi-specific…
Abstract Number: 0330 • ACR Convergence 2024
Baseline Interstitial Lung Disease (ILD) Characteristics and Outcomes in Patients with Anti-synthetase Syndrome Related ILD (ASSD-ILD): Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Francisca Bozan¹, Sangmee Bae², Daphne Rivero Gallegos³, Giovanni Zanframundo⁴, Sara Faghihi-Kashani⁵, Iazsmin Bauer Ventura⁶, Eduardo Dourado⁷, Darosa Lim⁸, Aravinthan Loganathan⁹, Gianluca sambataro¹⁰, Akira Yoshida¹¹, Francesco Bonella¹², Tamera J Corte¹³, Tracy J Doyle¹⁴, david fiorentino¹⁵, Miguel Angel Gonzalez-Gay¹⁶, marie Hudson¹⁷, Masataka Kuwana¹⁸, Antonella Notarnicola¹⁹, Andrew Mammen²⁰, Neil McHugh²¹, Frederick Miller²², Carlomaurizio Montecucco²³, Chester Oddis²⁴, Jorge Rojas-Serrano²⁵, Jens Schmidt²⁶, Carlo A. Scire²⁷, Ana Villar²⁸, Victoria Werth²⁹, Rohit Aggarwal³⁰ and Lorenzo Cavagna³¹, ¹Hospital Clinico Universidad de Chile, Santiago, Chile, ²UCLA, Los Angeles, CA, ³INER, Ciudad de México, Mexico State, Mexico, ⁴Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁶University of Chicago, Chicago, IL, ⁷Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁸University of Pennsylvania, Philadelphia, PA, ⁹RUH, Middle Park, Queensland, Australia, ¹⁰University of Catania, Catania, Italy, ¹¹Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹²Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹³Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹⁴Brigham and Women's Hospital, West Roxbury, MA, ¹⁵Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁶University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁷McGill University, Montreal, QC, Canada, ¹⁸Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁹Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ²⁰NIH, Bethesda, MD, ²¹University of Bath, Bath, United Kingdom, ²²NIH, NIEHS, Chapel Hill, NC, ²³IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁵National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁶University Medical Center Goettingen, Göttingen, Germany, ²⁷University of Milano Bicocca, Milan, Italy, ²⁸Systemic Autoimmune Diseases Unit, Internal Medicine Department, Vall d'Hebron University Hospital, Universitat Autònoma of Barcelona, Barcelona, Spain, Barcelona, Spain, ²⁹University of Pennsylvania, Wynnewood, PA, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, ³¹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy
Background/Purpose: Anti-synthetase syndrome (ASSD) is a systemic autoimmune rheumatic disorder with significant heterogeneity. ILD is the most common cause of mortality and an important prognostic…
Abstract Number: 1139 • ACR Convergence 2024
Comprehensive Single-cell Profiling of Diverse Circulating Immune Cells in Idiopathic Inflammatory Myopathies Identifies a Novel Pathogenic Subset of Monocytes
Shinji Izuka¹, Toshihiko Komai², Hayato Yuuki², Ikuko Ueda³, Manabu Fujimoto⁴, Hiroyuki Fukui⁵, Masaru Takeshita⁶, Natsuka Umezawa⁷, Shinsuke Yasuda⁷, Mitsutaka Yasuda⁸, Yuichiro Fujieda⁹, Tatsuya Atsumi⁹, Takeshi Iwasaki¹⁰, Akio Morinobu¹⁰, Yuya Kondo¹¹, Isao Matsumoto¹¹, Toshio Kawamoto¹², Masakazu Matsushita¹², Naoto Tamura¹³, Taro Iwamoto¹⁴, Hiroshi Nakajima¹⁴, Ken Yoshida¹⁵, Takeo Isozaki¹⁶, Nobuyuki Yajima¹⁶, Keiichi Sakurai¹⁷, Kimito Kawahata¹⁷, Yasuyuki Kamata¹⁸, Kojiro Sato¹⁸, Yoshiya Tanaka¹⁹, Akari Suzuki²⁰, Kazuhiko Yamamoto²¹, Tomohisa Okamura²² and Keishi Fujio², ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Bunkyo, Tokyo, Japan, ³Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Japan, ⁴Department of Dermatology, Osaka University Graduate School of Medicine, Suita, Japan., Suita, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan., Tokyo, Japan, ⁶Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁷Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan., Tokyo, Japan, ⁸Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan., Sapporo, Japan, ⁹Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ¹⁰Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan., Kyoto, Japan, ¹¹Department of Rheumatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan., Tsukuba, Japan, ¹²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ¹⁴Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan., Chiba, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁶Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan., Tokyo, Japan, ¹⁷Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan., Kawasaki, Japan, ¹⁸Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, Tochigi, Japan., Tochigi, Japan, ¹⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²⁰Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kanagawa, Japan, ²¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan., Kawasaki, Japan, ²²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan., Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan., Bunkyo, Tokyo, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are heterogeneous diseases, making it crucial to identify distinct pathological processes to improve a treatment strategy. Transcriptomic analyses have revealed…
Abstract Number: 1161 • ACR Convergence 2024
Characterization of the Clinical Presentation of Idiopathic Inflammatory Myopathies According to the Profile of Specific Autoantibodies with Multiple Positivity
Adriana Miguel-Álvarez¹, luis M Amezcua Guerra², María L Loredo-Mendoza¹, Luis H. Silveira Torre³ and Angélica Vargas Guerrero⁴, ¹Instituto Nacional de Cardiología "Ignacio Chávez", México, Distrito Federal, Mexico, ²Department of Immunology, Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ³Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁴Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico
Background/Purpose: The aim of this study is to assess if there are clinical and serological differences in patients with idiopathic inflammatory myopathies (IIM) according to…
Abstract Number: 1731 • ACR Convergence 2024
Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial
hector Chinoy¹, Ashma Krishan¹, Yvonne Sylvestre¹, James Lilleker², Patrick Gordon³, Sarah Tansley⁴, Athiveeraramapandian Prabu⁵, Aamir Aslam⁶, Andrew Snedden⁷ and Janine Lamb⁸, ¹The University of Manchester, Manchester, United Kingdom, ²Northern Care Alliance NHS Trust, Salford, United Kingdom, ³nhs, London, United Kingdom, ⁴University of Bath, Bath, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, ⁶Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁷Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, ⁸University of Manchester, UK, Manchester, United Kingdom
Background/Purpose: The aim of the study was to assess the effects of baricitinib, a JAK1/2 inhibitor, following 24 weeks of active treatment on disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].